Cargando…

Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy

AIM: Accurate causality assessment (CA) of adverse events (AEs) is important in clinical research and routine clinical practice. The Naranjo scale (NS) used for CA lacks specificity, leading to a high rate of false positive causal associations. NS is a simple scale for CA; however, its limitations h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Jyoti Bhagatram, Krishnamurthy, Manjunath Nookala, Awase, Ankita, Joshi, Amit, Patil, Vijay, Noronha, Vanita, Prabhash, Kumar, Gota, Vikram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882752/ https://www.ncbi.nlm.nih.gov/pubmed/33628419 http://dx.doi.org/10.1177/2042098621991280

Ejemplares similares

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
por: Gota, Vikram, et al.
Publicado: (2014)

ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients
por: Patil, Anand, et al.
Publicado: (2021)

Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia
por: Nookala Krishnamurthy, Manjunath, et al.
Publicado: (2020)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014)

Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers
por: Patil, Vijay M., et al.
Publicado: (2015)

Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer
por: Noronha, Vanita, et al.
Publicado: (2012)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study
por: Joshi, Amit, et al.
Publicado: (2018)

Effect of the Pandemic on Quality-of-Life Data Collection in Prostate Cancer Patients
por: Shirsat, Aditi, et al.
Publicado: (2021)

Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
por: Pandey, Avinash Vijaykumar, et al.
Publicado: (2015)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Lung cancer in the Indian subcontinent
por: Noronha, Vanita, et al.
Publicado: (2016)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal
por: Noronha, Vanita, et al.
Publicado: (2015)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer
por: Joshi, Amit, et al.
Publicado: (2016)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer
por: Shetty, Nishitha, et al.
Publicado: (2015)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
por: Kapoor, Akhil, et al.
Publicado: (2022)

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes
por: Wang, Jiun-Long, et al.
Publicado: (2021)

Confusion worse confounded
por: Noronha, Vanita, et al.
Publicado: (2013)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance
por: Patil, Vijay M., et al.
Publicado: (2015)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Long term outcomes of phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early failure oral cancer
por: Babanrao Dhumal, Sachin, et al.
Publicado: (2023)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy
por: Dhumal, Sachin Babanrao, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

A diagnostic dilemma in a patient with lymphoma
por: Shah, Kajal, et al.
Publicado: (2013)

Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fotajcak79hfotc6rf88o5lioh